Thou­sands of com­plaints and lab records in 'bags of scrap': FDA in­spects Cipla site in In­dia

An­oth­er man­u­fac­tur­ing site be­long­ing to Cipla is un­der the FDA’s mi­cro­scope.

An FDA in­spec­tion of one of Cipla’s man­u­fac­tur­ing sites in Pi­tham­pur, In­dia un­veiled sev­er­al qual­i­ty and da­ta ob­ser­va­tions be­tween Feb.6 and Feb. 23 of this year. Ac­cord­ing to the 483 re­port, the man­u­fac­tur­ing site re­ceived over 3,000 com­plaints be­tween 2020 and 2022. The FDA’s re­port al­so stat­ed that 266 com­plaints were al­so re­ceived this year and are still un­der in­ves­ti­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER